ACROBiosystems, a provider of tools and solutions used from discovery to the clinic, has announced a new corporate initiative to support ex vivo cell manufacturing and manufacturers of cell and gene therapies.
 
This initiative represents the company’s new mission of “overcoming challenges from discovery to the clinic with innovation”. Manufacturing operations are a critical component of translational medicine, transforming the small-scale needs in discovery into consistent, high-volume reagents required for the clinical phase and commercialization.

The launch of this initiative aims to streamline the transition from research to the clinic by offering progressive reagents at each stage. Inclusion of up-to-date regulatory documentation and support from regulatory professionals at each stage aims to help ensure success throughout the manufacturing and clinical process.
 
“Our commitment to independent research and innovation while overcoming technical bottlenecks increases our manufacturing agility by providing the best solutions to our customers when they need it,” said John Miao, Senior Vice President and Chief Operating Officer in a recent interview. “This commitment was reflected in the recent launch of GMP-grade DLL4, a safer recombinant protein alternative to DLL4 feeder cells often used in iPSC-derived T cell manufacturing.”